Human immunodeficiency virus infection and cerebral malaria in children in Uganda: a case-control study

Peace D Imani1*, Philippa Musoke1,2, Justus Byarugaba1, James K Tumwine1

Abstract

Background: Human immunodeficiency virus (HIV)-1 infection increases the burden of malaria by increasing susceptibility to infection and decreasing the response to malarial treatment. HIV-1 has also been found to suppress the immune system and predispose to severe forms of malaria in adults. There is still a paucity of data on the association between HIV-1 infection and cerebral malaria in children. The aim of this study was to determine whether HIV-1 infection is a risk factor for cerebral malaria in children.

Method: We conducted an unmatched case-control study, in which 100 children with cerebral malaria were compared with 132 with uncomplicated malaria and 120 with no malaria. In stratified analyses we estimated odds ratios (ORs) and 95% confidence intervals (CIs) adjusted for age.

Results: HIV-1 infection was present in 9% of children with cerebral malaria compared to 2.3% in uncomplicated malaria (age-adjusted odds ratio (aOR) 5.94 (95% confidence interval (CI) 1.36-25.94, p = 0.012); and 2.5% in children with no malaria (aOR 3.85 (95% CI0.99-14.93, p = 0.037). The age-adjusted odds of being HIV-positive among children with cerebral malaria compared to the control groups (children with uncomplicated malaria and no malaria) was 4.98 (95% CI 1.54-16.07), p-value = 0.003.

Conclusions: HIV-1 infection is associated with clinical presentation of cerebral malaria in children. Clinicians should ensure that children diagnosed with HIV infection are initiated on cotrimoxazole prophylaxis as soon as the diagnosis is made and caretakers counselled on the importance of adherence to the cotrimoxazole towards reducing the risk of acquiring P.falciparum malaria and associated complications such as cerebral malaria. Other malaria preventive measures such as use of insecticide-treated mosquito nets should also be emphasized during counselling sessions.

Background

Malaria and Human immunodeficiency virus (HIV)-1 are two of the most common global health challenges today and the two infections commonly overlap in distribution in most countries especially in sub-Saharan Africa [1]. Studies have demonstrated interaction between these two infections with the majority of studies conducted in adults [2-6]. HIV-1 infection has been found to be associated with severe forms of malaria and particularly cerebral malaria in adults but there is still a paucity of information on the interaction between the two infections in children [2,7,8].

HIV-1 infected adults have a greater percentage of severe malaria episodes with more frequent hospitalizations compared to their uninfected counterparts and are at a greater risk of cerebral malaria [2,3,7,9]. Infection with HIV-1 leads to impaired immune response to malaria through cellular immunosuppression resulting in a higher likelihood of increased parasitaemia and severe malarial infections. Multiple studies have indicated an alteration in cytokine levels in those co-infected with malaria and HIV [10-12].

Malaria-specific antibodies, the main target of protective malaria immunity seem to be little impaired in early HIV infection but in advanced AIDS, evidence indicates...
B-cell stimulation is diminished to some extent, resulting in decreased production of malaria antibodies [10,13]. HIV infection has also been found to increase the susceptibility to new malarial infections [3,9]. There is evidence also showing strong correlation between decreasing CD4+ cell counts and both the levels of parasitaemia and the patients' clinical status [12,14]. HIV-infected children with advanced immunosuppression have more episodes of clinical malaria and higher parasite densities compared to those children without advanced immunosuppression [15]. In children, cerebral malaria is the most severe neurological complication of *P. falciparum* malaria infection and has a case fatality ranging from 5 to 40% [16-19].

Whether HIV-1 infection increases the risk of cerebral malaria in children is not known. We conducted this study to determine whether HIV infection is a risk factor for cerebral malaria in children from Uganda.

**Methods**

We conducted a case-control study of children with cerebral malaria recruited from Mulago hospital Paediatric emergency unit. We also recruited 132 children with uncomplicated malaria and 120 with no malaria as controls from the paediatric outpatients units. Cases included children aged below 12 years with cerebral malaria [defined as a clinical syndrome characterized by coma: Blantyre Coma Scale (BCS) ≤ 2] for more than 30 minutes after termination of a seizure or correction of hypoglycaemia, detection of asexual forms of *P. falciparum* malaria parasites on peripheral blood smears, and a normal cerebrospinal fluid (CSF) [20]. The parasite density was determined after enrolment and was therefore not considered in the inclusion criteria. Severe anemia was not an inclusion criterion per se but children with severe anemia, who had a history of convulsions and were admitted with a BCS ≤ 2 (in coma), with a relatively normal blood sugar (at least above 2.2 mmol/l), normal electrolytes and a normal CSF, were included in the study.

Uncomplicated malaria was defined as fever with a positive blood smear for malaria parasites taken if the child was found to be HIV positive. The HIV tests were rapid and the children who were HIV positive had blood sent for CD4 cell count immediately. These were used to stage level of immunosuppression according to the WHO guidelines [22]. No repeat CD4 test was carried out after treatment. Serum electrolytes were assessed on all children with cerebral malaria. A lumbar puncture was performed on the children with suspected cerebral malaria and a normal CSF described as a specimen with a cell count of ≤5 WBC/mm³ and a CSF protein of ≤40 mg/dl. Patients with cerebral malaria and those with uncomplicated malaria received standard care according to the Mulago Hospital Department of Paediatrics guidelines. Those without malaria were seen by the surgeons who offered appropriate treatment for the surgical condition. HIV positive children were referred to the Paediatric Infectious Disease Clinic (PIDC) where they were evaluated, managed and followed up. The number of asexual parasites per 200 white blood cells (WBCs) was counted and parasite densities computed by assuming a mean WBC count of 8,000/litre (WHO) [23].

The primary objective of this study was to assess HIV-1 as an independent risk factor for cerebral malaria. The secondary objective was to determine the
prevalence of HIV-1 infection in children with cerebral malaria and the correlation between the level of immuno-suppression (CD4+ T-cell count) and parasite density.

Statistical Analysis
Data was entered into EPI-DATA 3.1 software package and analysed using the statistical program SPSS version 13 software packages. Categorical variables were summarized as proportions while means and standard deviation were used for normally distributed continuous variables. Medians with corresponding inter-quartile ranges were used for skewed data. The Chi-square test was used to compare categorical variables between those cerebral malaria and those without. Multivariate analysis (logistic regression by backward method) was then used to tease out whether HIV infection is independently associated with clinical cerebral malaria.

Ethics and Consent
Informed consent to participate in the study was obtained from the caretakers after explanation of the study objectives and relevance, risks and benefits. A separate consent for HIV testing was also obtained. Laboratory results were available for patient management. Approval was obtained from the Makerere University Faculty of Medicine, Research and Ethics Committees, Mulago Hospital, and the Uganda National Council of Science and Technology.

Results
The study was conducted from November 2006 to March 2007 during which 352 children were recruited. One hundred had cerebral malaria (CM), 132 had uncomplicated malaria (UM) and 120 had no malaria (NM). Thirty two patients with suspected cerebral malaria were excluded, 28 of whom we could not do complete assessment and 4 had incomplete data. Ten percent (13/133) of children with no malaria were found with asymptomatic parasitaemia and these were also excluded from the analysis Figure 1. Children hospitalized with cerebral malaria were more likely to be less than five years of age (81% vs 68% and 63%) and not to use mosquito nets (54% vs 86% and 63% in the uncomplicated malaria and no malaria arms respectively). Of the 352 children enrolled, 3 (2 cases and 1 control) had moderate to severe wasting (Table 1a).

Children with cerebral malaria also had median serum sodium of 137.0 mmol/L (range 131-142 mmol/L). One patient had severe hypoglycaemia at the time of enrolment (blood sugar below 2.2 mmol/L). The median blood sugar was 7.4 mmol/L (range 5.9-9.5 mmol/L). Thirty eight percent of patients with CM had severe anaemia (Hb < 5 g/dl). No microbiological culture or virological tests were done on the CSF since the white blood cell count was not raised.

Children with cerebral malaria who were also HIV positive children were more likely to have had fever for more than three days, been on treatment prior to this admission, present with higher temperatures (>38°C) and have a higher parasite density (Table 1b). HIV positive children with cerebral malaria were also more likely to have a higher parasite density. The unadjusted odds of having parasite density greater than 500,000/μl with cerebral malaria was 12.71 times higher in HIV positive children (95% CI; 0.77-189.57) compared to those who were HIV negative. The age-adjusted OR was 13.76 (95% CI; 1.24-153.11), p-value = 0.0051.

Sixty seven (56%) of the 120 controls with no malaria recruited from SOPD had inguino-scrotal hernias, 26 (22%) presented with hydroceles, and the others had congenital anorectal malformations, umbilical hernias, undescended testis, rectal prolapse and different types of cysts. None of these controls required urgent intervention but only an appointment for elective surgery. Ideally, these controls (no malaria) would have been selected from similar communities as the cases but this was not the case due to limited funds for this. This could have potentially caused bias in the HIV prevalence. The prevalence of HIV was 9% among children with cerebral malaria compared to 2.3% and 2.5% in the uncomplicated malaria and no malaria groups respectively.

There was an association between HIV infection and clinical cerebral malaria, HIV infected children were more likely to have cerebral malaria than the HIV negative ones, unadjusted OR = 4.05 (95%CI 1.24-14.19), p = 0.006 and age-adjusted odds ratio (aOR) was 4.98 (95% CI 1.54-16.07) p = 0.003. Among children below the age of 5 years, the HIV prevalence in cerebral malaria cases was 8.6% (7 of 81) compared to 1.2% (2 out of 166) among all controls. The odds of presenting with clinical cerebral malaria below the age of five was higher among children who were HIV positive compared to the HIV negative counter parts OR = 7.76 (95% CI; 1.42-77.6); p-value 0.003 (Table 2).

On comparing the children with cerebral malaria to those with the no malaria, the age-adjusted odds of presenting with cerebral malaria was 3.85 times higher among HIV positive children compared to HIV negative ones, (95% CI = 0.99-14.93) p = 0.037. The aOR was 5.94 (95% CI 1.36-25.94) when comparing children with cerebral malaria to children with uncomplicated malaria, p-value 0.012 (Table 3). Table 4 shows a summary of the age-adjusted odds ratios comparing the cases to the control groups.

The CD4 lymphocyte percentage and absolute counts were used to determine the stage of HIV immunosuppression. Twenty percent HIV-positive children had their stage of immune suppression by CD4 count corresponding to their WHO clinical stage. Fifty five
percent of the HIV-infected children with cerebral malaria were not clinically immunosuppressed or just had mild immunosuppression compared to 16.7% of HIV positive children with uncomplicated or no malaria. Children with cerebral malaria were more likely to have mild to moderate immunosuppression than were children without cerebral malaria (age-adjusted OR = 3.33 (95%CI 0.25-45.11); p-value = 0.336). However, the numbers of HIV positive children in this sample was very small.

Discussion
Our results are in agreement with studies conducted in Kwazulu Natal, South Africa and in Kenya where researchers in those countries also found similar association with HIV infection and severe malaria in children [9,24,25]. In South Africa, the prevalence of HIV among children with severe malaria was 17% compared to 7.5% in children with uncomplicated malaria while the study in Kenya, found a prevalence of 12% among children admitted with severe malaria. In both studies, the forms of severe malaria which the children presented with and HIV prevalence in cerebral malaria were not reported.

The prevalence of HIV was lower than expected in this study population probably because of early HIV testing and diagnosis and initiation of cotrimoxazole prophylaxis for children found to be HIV positive which would also be protective against P. falciparum malaria and severe forms of malaria [14,26,27]. None of the HIV positive patients had been on prior cotrimoxazole prophylaxis since their HIV status was unknown at the time of enrolment.

HIV infected children in this study were more likely to have hyperparasitaemia (parasite density >500,000/μl) which was consistent with what was found in studies in the Kenya and Zimbabwe studies in which HIV infection was associated with higher parasite density [2,25]. Presumably, HIV infected children are less likely to clear parasites from their blood than the non HIV infected children because HIV infection impairs the immune response to malaria parasites, leading to decreased ability to control parasitaemia [2,5,28,29]. The high parasitaemia places these children at a higher risk of developing cerebral malaria because of the increased likelihood of having the parasites sequester in the capillary blood vessels. It is also possible that HIV-infected children are at increased risk of developing cerebral malaria because of an increased production of nitric oxide synthase, ICAM-1 and VCAM-1 with HIV infection [30]. Nitric oxide has been suggested as a cause for coma because of its ability to interfere with neurotransmission in the brain [30,31]. However, other studies have found no significant association with cerebral malaria [32].

Due to the low number of HIV infected children in our controls, we found no association between cerebral malaria and low CD4 cell count. A longitudinal study in

---

**Figure 1** Study profile.
Table 1 Baseline characteristics of study population

| Variable                                      | Cerebral malaria | Uncomplicated malaria | No malaria |
|-----------------------------------------------|------------------|------------------------|------------|
| **a. Characteristics of all children and their care takers** | n = 100          | n = 132                | n = 120    |
| **Child factors**                             | N (%)            | N (%)                  | N (%)      |
| **Age (Months)**                              |                  |                        |            |
| ≤59                                           | 81 (81)          | 90 (68.2)              | 76 (63.3)  |
| >59                                           | 19 (19)          | 42 (31.8)              | 44 (36.7)  |
| **Sex M:F**                                   | 01:00.7          | 01:00.7                | 01:00.7    |
| **Median duration of fever in days (IQR)**    | 3 (2-4)          | 2 (1-4)                | -          |
| **Use of mosquito net**                       |                  |                        |            |
| Yes                                           | 54 (54)          | 86 (65.2)              | 63 (52.5)  |
| No                                            | 46 (46)          | 46 (34.8)              | 57 (47.5)  |
| **Immunization status**                       |                  |                        |            |
| Fully/up-to-date                              | 73 (73)          | 102 (77.3)             | 105 (87.5) |
| Partial/uncertain                             | 27 (27)          | 30 (22.7)              | 15 (12.5)  |
| **Pre-hospital treatment**                    |                  |                        |            |
| Yes                                           | 82 (82)          | 76 (57.6)              | -          |
| No                                            | 18 (18)          | 56 (42.4)              |            |
| **Median parasite density (IQR)**             | 23480 (1660-145960) | 21680 (7350-54300)     |            |
| **HIV status**                                |                  |                        |            |
| Positive                                      | 9 (9)            | 3 (2.3)                | 3 (2.5)    |
| Negative                                      | 91 (91)          | 129 (97.7)             | 117 (97.5) |
| **Caretaker factors**                         |                  |                        |            |
| **Age of caretaker (in years)**               |                  |                        |            |
| ≤30                                           | 70 (70.0)        | 103 (78.0)             | 63 (52.5)  |
| >30                                           | 30 (30.0)        | 29 (22.0)              | 57 (47.5)  |
| **Antimalarial medicines kept at home**       |                  |                        |            |
| Yes                                           | 28 (28)          | 36 (27.3)              | 25 (20.8)  |
| No                                            | 72 (72)          | 96 (72.7)              | 95 (79.2)  |
| **Caretaker’s preferred first option**        |                  |                        |            |
| H/U†                                          | 25 (25)          | 44 (33.3)              | 93 (77.5)  |
| Other‡                                        | 75 (75)          | 88 (66.7)              | 27 (22.5)  |
| **Number of children <5y in the household**   |                  |                        |            |
| ≤3                                            | 83 (83)          | 124 (93.9)             | 79 (64.9)  |
| >3                                            | 17 (17)          | 8 (6.1)                | 14 (15.1)  |
| **b. Characteristics of cerebral malaria patients by HIV status** | HIV+ (n = 9) | HIV- (n = 91) | P-value OR (95% CI) |
| **Age**                                       |                  |                        |            |
| ≤59 Mo                                        | 7 (77.8)         | 74 (81.3)              |            |
| >59 Mo                                        | 2 (22.2)         | 17 (18.7)              |            |
| **Duration of fever (days)**                  |                  |                        |            |
| ≤3                                            | 5 (55.6)         | 59 (35.2)              | 0.58       |
| >3†                                           | 4 (44.4)         | 32 (64.8)              | 1.48 (0.27-7.37) |
| **Median number of convulsions (IQR)**        | 3 (2-3)          | 2 (1-5)                |            |
| **Pre-hospital treatment**                    |                  |                        |            |
| Yes†                                          | 6 (66.7)         | 76 (83.5)              | <0.001     |
| No                                            | 3 (33.3)         | 15 (16.5)              | 3.36 (1.81-6.21) |
| **Median parasite density (IQR)**             | 240,000 (3080-583520) | 21,440 (1600-133080)   |            |
| **Parasite density/μl**                       |                  |                        |            |
| >500,000†                                     | 2 (22.2)         | 2 (2.19)               | 0.003      |
| ≤500,000                                      | 7 (77.8)         | 89 (97.8)              | 12.71 (1.56-10441) |

n = number of children, IQR = Inter-quartile range, 1skilled laborers, 2 tepid sponging/self-medication/herbs, H/U = health unit, † reference group.
Malawi has already indicated that lower CD4 cell counts were associated with higher incidences of pneumonia, sepsis, and tuberculosis but not of malaria [33]. Other factors found to be associated with an increased risk of presenting with clinical cerebral malaria were age below five years and not using a mosquito net. These findings are also consistent with previous studies [16,34,35].

Our findings support the hypothesis that HIV infection is a risk factor for cerebral malaria in children. The findings from this study add to the existing knowledge of interaction between HIV infection and *P. falciparum*

### Table 2 Comparing cerebral malaria and no malaria groups

| Variable                        | Cerebral Malaria | No Malaria | Unadjusted p-value | Adjusted OR (95% CI) |
|---------------------------------|------------------|------------|---------------------|----------------------|
| Age (Months)                    |                  |            |                     |                      |
| ≤59†                            | 81 (81)          | 76 (63.3)  | 0.004               | 0.004                |
| >59                             | 19 (19)          | 44 (36.7)  | 2.47 (1.27-4.88)    | 2.49 (1.30-4.75)†    |
| Use of mosquito net             |                  |            |                     |                      |
| Yes†                            | 46 (46)          | 57 (47.5)  | 1.06 (0.62-1.81)    | 0.99 (0.57-1.71)‡    |
| No                              |                 |            |                     |                      |
| HIV status                      |                  |            |                     |                      |
| Positive†                       | 9 (9)            | 3 (2.5)    | 0.035               | 0.037                |
| Negative                        |                 |            |                     |                      |
| Caretaker’s preferred first option H/U |          |            |                     |                      |
| Yes†                            | 25 (25)          | 93 (72.5)  | <0.001              | <0.001               |
| No†                             | 75 (75)          | 27 (22.5)  | 10.33 (4.96-21.52)  | 9.93 (4.77-20.68)‡   |
| Number of children <5y/household|                  |            |                     |                      |
| ≤3                              | 83 (83)          | 79 (84.9)  | 0.714               |                      |
| >3†                             | 17 (17)          | 14 (15.1)  | 1.16 (0.53-2.51)    |                      |

n = number of children, CI confidence interval, OR odds ratio, H/U = health facility, † reference group, ¶ adjusted for HIV, ‡adjusted for age, CM = cerebral malaria, NM = no malaria.

### Table 3 Comparing cerebral malaria and uncomplicated malaria

| Variable                        | Cerebral Malaria | Uncomplicated Malaria | Unadjusted p-value | Adjusted OR (95% CI) |
|---------------------------------|------------------|-----------------------|--------------------|----------------------|
| Age (Months)                    |                  |                       |                    |                      |
| ≤59†                            | 81 (81)          | 90 (68.2)             | 0.028              | 0.016                |
| >59                             | 19 (19)          | 42 (31.8)             | 1.99 (1.07-3.69)   | 2.41 (1.14-4.02)‡    |
| Use of mosquito net             |                  |                       |                    |                      |
| Yes†                            | 54 (54)          | 86 (65.2)             | 0.086              | 0.051                |
| No†                             | 46 (46)          | 46 (34.8)             | 0.63 (0.37-1.07)   | 0.58 (0.34-1.01)¶    |
| Pre-hospital treatment          |                  |                       |                    |                      |
| Yes†                            | 82 (82)          | 76 (57.6)             | <0.001             | 0.002                |
| No†                             | 18 (18)          | 56 (42.4)             | 3.36 (1.81-6.21)   | 3.02 (1.52-5.99)¶    |
| Median parasite density/μl      |                  |                       |                    |                      |
| >500,000†                       | 4 (4)            | 1 (0.76)              | 0.092              | 0.069                |
| ≤500,000                        | 96 (96)          | 131 (99.24)           | 5.46 (0.53-270.77) | 5.23 (0.71-38.59)¶   |
| HIV status                      |                  |                       |                    |                      |
| Positive†                       | 9 (9)            | 3 (2.3)               | 0.022              | 0.012                |
| Negative                        | 91 (91)          | 129 (97.7)            | 4.25 (1.10-16.64)  | 5.94 (1.23-28.72) ¶  |
| Number of children <5y/household|                  |                       |                    |                      |
| ≤3                              | 83 (83)          | 124 (93.9)            | 0.008              | 0.005                |
| >3†                             | 17 (17)          | 8 (6.1)               | 3.18 (1.31-7.69)   | 4.03 (1.51-10.76)¶   |

CI = confidence interval, OR odds ratio, † adjusted for HIV status, ¶ age-adjusted OR, ‡reference group, CM = cerebral malaria, UM = uncomplicated malaria.
malaria in children and are of both clinical and public health importance.

Conclusions
HIV-1 infection is associated with clinical presentation of cerebral malaria in children. Clinicians should ensure that children diagnosed with HIV infection are initiated on cotrimoxazole prophylaxis as soon as the diagnosis is made and caretakers counselled on the importance of adherence to the cotrimoxazole towards reducing the risk of acquiring *P. falciparum* malaria and associated complications such as cerebral malaria. Other malaria preventive measures such as use of insecticide-treated mosquito nets should also be emphasized during counselling sessions.

Study Limitations
There are sources of potential sources of bias that cannot be eliminated in this study. These inherent sources include selection of no malaria controls from a hospital setting which may have affected our results. We however tried to limit this by selecting hospital controls from similar communities. We also excluded children with conditions clearly documented to be associated with HIV such as pneumonia, severe malnutrition, persistent diarrhoea, and chronic otitis media. The design of the study may have also affected the results. The case control design may have led to exaggeration of the risk because cases and controls were not matched on characteristics such as age, maternal characteristics and others. The parasite density may not be a true reflection of the level of parasitaemia since the individual WBC count was not available to estimate the parasite density but instead assumed 8,000/μL. There is a possibility that the WBC count was different in HIV+ and HIV- children.

Children with cerebral malaria were not followed up to determine whether the outcome depended on HIV serostatus. The strength of the study is that there were more than one control groups and given that cerebral malaria is a relatively rare complication of malaria, it was an appropriate study design to conduct given the time.

Acknowledgements
We thank the staff of Mulago Assessment Centre, Paediatrics Surgical Outpatient Clinic and Acute Care Unit and the staff at the Malaria clinic, Uganda Heart Institute and MU-JHU laboratories for all the support and all the study participants. We are also grateful to Mr Yusuf Mulumba, for the statistical data analysis and special thanks to Dr. Immaculate Ampeire and matron Segwanyi for helping with the data collection.

Financial support
The Malaria Consortium through the Malaria Research Council, Dr E. Mworozi and Mr. T. Forrest.

Table 4 Association between cerebral malaria and HIV infection comparing CM to both control groups

|                | CM and UM OR (95% CI) | CM and NM OR (95% CI) | CM and (NM + UM) OR (95% CI) |
|----------------|-----------------------|-----------------------|-----------------------------|
| All children   | 5.94 (1.23-28.72)‡    | 3.85 (0.98-15.07)‡    | 4.98 (1.54-16.07)‡          |
| Excluding children >5 year | 3.50 (0.69-17.34)    | 7.76 (1.52-39.47)    |

‡ adjusted for age, CM = cerebral malaria, UM = uncomplicated malaria, NM = no malaria.

References
1. Abu-Raddad L, Patnaik P, Kublin J: Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. *Science* 2006, 314(5805):1603-6.
2. Chirenda J, Saya S, Tshimanga M: Association of HIV infection with the development of severe and complicated malaria cases at a rural hospital in Zimbabwe. *Cent Afr J Med* 2000, 46(1):5-9.
3. Kamya M, Gasasira A, Yeka A, Bakyaita N, Nsobya S, Francis D, et al: Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. *J Infect Dis* 2006, 193(1):9-15.
4. Cohen C, Karastaedt A, Frean J, Thomas J, Govender N, Prentice E, et al: Increased prevalence of severe malaria in HIV-infected adults in South Africa. *Clin Infect Dis* 2005, 41(1):163-7.
5. Patnaik P, Jere CS, Miller WC, Hoffman IF, Winma J, Pendant R, et al: Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. *J Infect Dis* 2005, 192(6):984-91.
6. Hewitt K, Steketee R, Mwapaasa V, Whitworth J, French N: Interactions between HIV and malaria in non-pregnant adults: evidence and implications. *AIDS* 2006, 20(16):1993-2004.
7. Chirenda J, Murugasampillay S: Malaria and HIV co-infection: available evidence, gaps and possible interventions. *Cent Afr J Med* 2003, 49(5-6):62-71.
8. Chirwa V, Van Geertruyden J, Mukwamata B, Menten J, Kamalamba J, Mulenga M, et al: Increased risk for severe malaria in HIV-1-infected adults, Zambia. *Emerg Infect Dis* 2009, 15(5):749, quiz 858.
9. Grimwade K, French N, Mbatha DD, Zungu DD, Dedicoat M, Gilks CF: HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. *AIDS* 2004, 18(3):547-54.
10. Chataivaneeyakorn S, Moore J, Otieno J, Chaiyaroj S, Perkins D, Shi Y, et al: Immunity to placental malaria. III. Impairment of interleukin(IL)-12, not IL-18, and interferon-inducible protein-10 responses in the placental intervillous blood of human immunodeficiency virus/malaria-coinfected women. *J Infect Dis* 2002, 185(1):127-31.
selected P. falciparum specific immune responses are
maintained in AIDS adults in Burkina Faso. Parasite Immunol 1996, 18(7):333-9.

13. Van Geertruyden J, Van Eijk E, Yosaatmadja F, Kasongo W, Mulenga M, D’Alessandro U, et al. The relationship of Plasmodium falciparum humeral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia. Malar J 2009, 8:296.

14. Merjin J, Lule J, Elekaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364(9443):1428-34.

15. Greenberg A, Nwa W, Ryder R, Medi M, Nzeza M, Kitadi N, et al. Plasmodium Falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children. N Engl J Med 1991, 325(2):105-9.

16. Angoy I, Pam S, Säljöhetra R. Clinical pattern and outcome in children with acute severe falciparum malaria at Jos University Teaching Hospital, Nigeria. East Afr Med J 1996, 73(12):823-6.

17. Nderezi G. Clinical trial to compare the efficacy of intramuscular Chloroquine with intramuscular Quinine in the treatment of cerebral malaria in children. Kampala: Makerere University; 1992.

18. Idro R, Karamagi C, Tumwine J. Immediate outcome and prognostic factors for cerebral malaria among children admitted to Mulago Hospital, Uganda. Ann Trop Paediatr 2004, 24(1):17-24.

19. Aceng J, Byarugaba J, Tumwine J. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. BMJ 2005, 330(7487):334.

20. Guidelines for treatment of malaria. World Health Organization; 2010.

21. Fless : Statistical Methods for Rates and Proportions. Wiley; 2 1981, 38-45.

22. Antiretroviral treatment of HIV infection in infants and children in resource-limited settings, towards universal access. World Health Organization, 2005.

23. Basic Laboratory Methods in Medical Parasitology. World Health Organization; 1991.

24. Grimwade K, French N, Mbatia OD, Zungu DD, Dedicoat M, Gilks CF. Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect Dis J 2003, 22(12):1057-63.

25. Berkley J, Bejon P, Twonge R, Gwer S, Maitland K, Williams T, et al: An evaluation of artesunate for the treatment of severe malaria in children in Kenya. Trop Med Int Health 2000, 5(8):553-61.

26. Merjin J, Elekaru JP, Liechty CA, Were W, Downing R, Ransom R, et al: Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006, 367(9518):1256-61.

27. Whitworth J, Morgan D, Quigley M, Smith A, Mayanja B, Etoh H, et al: Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000, 356(9233):1051-6.

28. French N, Nakijinyi J, Lugada E, Wateira C, Whitworth JA, Gilks CF. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001, 15(7):997-906.

29. Mannick JB, Stumler JS, Teng E, Simpson N, Lawrence J, Jordan J, et al. Nitric oxide modulates HIV-1 replication. J Acquir Immun Defic Syndr 1999, 22(1):1-9.

30. Maneerat Y, Vinyavejakul P, Punpoowong B, Jones M, Wilairatana P, Pongponratn E, et al: Inducible nitric oxide synthase expression is increased in the brain in fatal cerebral malaria. Histopathology 2000, 37(3):269-77.

31. Nyongabo T, Deloron P, Aubry P, Ndaruigire F, Manirakiza F, Muhinwa G, et al: Prognostic indicators in adult cerebral malaria: a study in Burundi, an area of high prevalence of HIV infection. Acta Trop 1994, 56(4):299-305.

32. Lauter M, van Oosterhout J, Thising P, Thumba F, Zijlstra E, Graham S, et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 2005, 193(6):872-8.

33. Satpathy S, Mohanty N, Panda P, Samal G. Severe falciparum malaria. Indian J Pediatr 2004, 71(2):133-5.

34. Safeukui-Noubissi I, Ranza S, Pouidougou B, Keita M, Traoré A, Traoré D, et al. Risk factors for severe malaria in Bamako, Mali: a matched case-control study. Microbes Infect 2004, 6(6):572-8.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2431/11/5/prepub

doi:10.1186/1471-2431-11-5

Cite this article as: Imani et al.: Human immunodeficiency virus infection and cerebral malaria in children in Uganda: a case-control study. BMC Pediatrics 2011 11:5.